AMOTL2
Angiomotin-like protein 2
Protein Summary
Regulates the translocation of phosphorylated SRC to peripheral cell-matrix adhesion sites. Required for proper architecture of actin filaments. Inhibits the Wnt/beta-catenin signaling pathway, probably by recruiting CTNNB1 to recycling endosomes and hence preventing its translocation to the nucleus. Participates in angiogenesis. May play a role in the polarity, proliferation and migration of endothelial cells. Selectively promotes FGF-induced MAPK activation through SRC. Angiomotin is a protein that binds angiostatin, a circulating inhibitor of the formation of new blood vessels (angiogenesis). Angiomotin mediates angiostatin inhibition of endothelial cell migration and tube formation in vitro. The protein encoded by this gene is related to angiomotin and is a member of the motin protein family. Alternative splicing results in multiple transcript variants of this gene. [provided by RefSeq, Jul 2013]
- ENST00000249883
- ENSP00000249883
- ENSG00000114019
- ENST00000422605
- ENSP00000409999
- ENST00000513145
- ENSP00000425475
- ENST00000514516
- ENSP00000424765
- KIAA0989
- LCCP
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
virus perturbation | 0.9 | ||
kinase perturbation | 0.88 | ||
PubMedID | 0.86 | ||
transcription factor binding site profile | 0.8 | ||
disease perturbation | 0.79 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 30.41 (req: < 5)
Gene RIFs: 16 (req: <= 3)
Antibodies: 93 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 30.41 (req: >= 5)
Gene RIFs: 16 (req: > 3)
Antibodies: 93 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 6
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0